1. Pink Sheet

Japan Eyes Cutting Reimbursement For COVID-19 Drugs

Large Reduction For Xocova?

 
• By Lisa Takagi

Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.

Balancing NHI system and the market’s demand for accessible drugs for COVID-19 can be a challenging task.
Japan's challenge to balance NHI system and market demand for COVID-19 drugs • Source: Shutterstock

The Japanese government may end 100% reimbursement coverage for several COVID-19 therapeutic drugs under the national health insurance (NHI) system from this October.

The Ministry of Health, Labour and Welfare (MHLW) has indicated it will continue full coverage until at least the end of September, after which it will "re-consider"

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Asia